Odonate Therapeutics Inc (NASDAQ:ODT) Receives Consensus Recommendation of “Strong Buy” from Brokerages

Odonate Therapeutics Inc (NASDAQ:ODT) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 1 year consensus target price of $45.00 for the company and are forecasting that the company will post ($1.07) earnings per share for the current quarter, according to Zacks. Zacks has also given Odonate Therapeutics an industry rank of 97 out of 256 based on the ratings given to its competitors.

Several analysts have recently commented on the company. Zacks Investment Research raised Odonate Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. ValuEngine downgraded Odonate Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Finally, Cowen reissued a “buy” rating on shares of Odonate Therapeutics in a research note on Monday, June 3rd.

In other Odonate Therapeutics news, Director Jeff L. Vacirca purchased 19,231 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The stock was bought at an average cost of $26.00 per share, with a total value of $500,006.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Boxer Capital, Llc purchased 384,615 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The shares were acquired at an average cost of $26.00 per share, with a total value of $9,999,990.00. The disclosure for this purchase can be found here. Insiders have purchased 1,393,077 shares of company stock valued at $36,230,094 over the last ninety days. 59.30% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC increased its position in Odonate Therapeutics by 2.6% in the second quarter. Janus Henderson Group PLC now owns 1,315,426 shares of the company’s stock worth $48,262,000 after buying an additional 33,325 shares during the last quarter. BlackRock Inc. increased its position in Odonate Therapeutics by 55.4% in the second quarter. BlackRock Inc. now owns 578,823 shares of the company’s stock worth $21,236,000 after buying an additional 206,238 shares during the last quarter. Eagle Asset Management Inc. purchased a new stake in Odonate Therapeutics in the second quarter worth $18,393,000. Redmile Group LLC increased its position in Odonate Therapeutics by 4.5% in the first quarter. Redmile Group LLC now owns 477,464 shares of the company’s stock worth $10,557,000 after buying an additional 20,513 shares during the last quarter. Finally, Carillon Tower Advisers Inc. purchased a new stake in Odonate Therapeutics in the second quarter worth $16,876,000. 77.79% of the stock is owned by institutional investors.

Shares of Odonate Therapeutics stock traded down $0.63 on Friday, hitting $33.97. The company had a trading volume of 1,340 shares, compared to its average volume of 86,377. The firm has a market capitalization of $1.15 billion, a PE ratio of -9.37 and a beta of 1.69. Odonate Therapeutics has a 1 year low of $11.54 and a 1 year high of $43.75. The stock’s 50 day simple moving average is $36.67.

Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings data on Wednesday, July 24th. The company reported ($1.15) EPS for the quarter, topping the consensus estimate of ($1.24) by $0.09. As a group, analysts predict that Odonate Therapeutics will post -4.62 EPS for the current fiscal year.

Odonate Therapeutics Company Profile

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Read More: Golden Cross

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.